The Emerging Role of RAS Inhibitors in Pancreatic Cancer
Midhun Malla, MD
Michael A. Morse, MD, FACP, MHS
Benjamin Leon Musher, MD
Janie Y. Zhang, MD
Rahul Gosain, MD, MBA
Rohit Gosain, MD
Key Points
- RAS inhibitors are generating excitement as emerging treatment options in pancreatic cancer.
- Patients responding to chemotherapy should not necessarily transition prematurely to targeted therapy.
- Dermatologic toxicities remain a notable challenge with RAS-directed agents.
- Future studies may move RAS inhibitors into earlier disease settings, including frontline and adjuvant therapy.
At a Clinical Insights discussion coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, cohosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, welcomed panelists Midhun Malla, MD, of the University of Alabama; Michael A. Morse, MD, FACP, MHS, of Duke Cancer Center; Benjamin Leon Musher, MD, of Baylor College of Medicine; and Janie Y. Zhang, MD, of the University of Pittsburgh, to explore the rapidly evolving role of RAS-targeted therapies in metastatic pancreatic adenocarcinoma. The panel described growing enthusiasm surrounding emerging KRAS-directed agents while cautioning that chemotherapy remains the backbone of treatment.
Dr. Morse noted that patients are increasingly aware of RAS inhibitor development through media coverage and growing visibility at major oncology meetings. Promising efficacy signals have generated excitement, but he emphasized that patients who respond well to frontline chemotherapy should not necessarily abandon effective treatment prematurely. Current evidence suggests that targeted therapies will likely complement rather than replace established chemotherapy regimens, particularly as more data emerge regarding optimal sequencing strategies.
Dr. Zhang discussed early clinical experience with emerging RAS-targeted agents, including investigational therapies being evaluated through expanded access programs and ongoing clinical trials. She reported durable responses in some patients treated with these agents but also highlighted important toxicities, particularly dermatologic adverse events. Although many patients may accept rash and skin toxicity in exchange for disease control, these adverse effects can significantly affect quality of life and require proactive management.
The panel concluded that for the foreseeable future, chemotherapy will remain a central component of metastatic pancreatic cancer treatment. Dr. Musher cautioned against abandoning effective maintenance chemotherapy simply to transition to a targeted therapy, noting that resistance mechanisms and sequencing strategies are still being investigated. At the same time, experts expressed optimism that RAS-directed therapies may move into earlier lines of treatment and eventually into perioperative and adjuvant settings. As data continue to emerge, integrating targeted therapy with established chemotherapy backbones may represent the next major advance in pancreatic cancer care.